Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
Trk Receptor

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Trk Receptor

Chemical Structure Cat. No. Product Name CAS No.
AZ-23 Chemical Structure
BCP01916 AZ-23 915720-21-7
AZ-23 is a potent and selective tyrosine kinase (Trk) inhibitor having potential for therapeutic utility in neuroblastoma and multiple other cancers.
PF-06273340 Chemical Structure
BCP29619 PF-06273340 1402438-74-7
PF-06273340 is a potent, selective, and peripherally restricted Pan-Trk Inhibitor with an excellent LipE profile (IC50 value: Trk-A = 6 nM; Trk-B = 4 nM; Trk-C = 3 nM).
Belizatinib Chemical Structure
BCP29521 Belizatinib 1357920-84-3
Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
ARRY470 Chemical Structure
BCP16262 ARRY470 1223403-58-4
Larotrectinib, also known as ARRY-470 and LOXO-101, is an orally bioavailable, potent, ATP-competitive inhibitor of TRKA, TRKB, and TRKC.
Tavilermide Chemical Structure
BCP24696 Tavilermide 263251-78-1
Tavilermide is a nerve growth factor mimetic.
Tyrphostin AG 879 Chemical Structure
BCP08354 Tyrphostin AG 879 148741-30-4
Tyrphostin AG 879 is a protein tyrosine kinase inhibitor with potent effects on TrkA.
TPX-0005 Chemical Structure
BCP19778 TPX-0005 1802220-02-5
TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively.
LM 22A4 Chemical Structure
BCP24795 LM 22A4 37988-18-4
LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.
GW441756 Chemical Structure
BCP01912 GW441756 504433-23-2
GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2.
Altiratinib Chemical Structure
BCP15682 Altiratinib 1345847-93-9
Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
12下一页共 16 条记录 1 / 2 页 
0086-13720134139